Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
2.815
+0.060 (2.18%)
Nov 20, 2024, 4:00 PM EST - Market closed
Galectin Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Selling, General & Admin | 5.88 | 5.94 | 6.62 | 6.36 | 5.47 | 5.97 | |
| Research & Development | 33.69 | 32.13 | 31.74 | 23.82 | 17.98 | 7.47 | |
| Operating Expenses | 39.57 | 38.07 | 38.35 | 30.18 | 23.44 | 13.44 | |
| Operating Income | -39.57 | -38.07 | -38.35 | -30.18 | -23.44 | -13.44 | |
| Interest Expense | -4.66 | -2.79 | -1.03 | -0.49 | -0.09 | -0.09 | |
| Interest & Investment Income | 0.33 | 0.23 | 0.05 | 0 | 0.07 | 0.23 | |
| Other Non Operating Income (Expenses) | -1.18 | -0.43 | 0.56 | 0.14 | - | - | |
| EBT Excluding Unusual Items | -45.08 | -41.07 | -38.78 | -30.53 | -23.47 | -13.29 | |
| Pretax Income | -45.08 | -41.07 | -38.78 | -30.53 | -23.47 | -13.29 | |
| Net Income | -45.08 | -41.07 | -38.78 | -30.53 | -23.47 | -13.29 | |
| Preferred Dividends & Other Adjustments | 0.15 | 3.74 | 0.1 | 0.17 | 0.14 | 6.89 | |
| Net Income to Common | -45.23 | -44.81 | -38.87 | -30.7 | -23.6 | -20.18 | |
| Shares Outstanding (Basic) | 62 | 60 | 59 | 59 | 57 | 52 | |
| Shares Outstanding (Diluted) | 62 | 60 | 59 | 59 | 57 | 52 | |
| Shares Change (YoY) | 4.27% | 1.29% | 1.48% | 2.63% | 9.17% | 32.54% | |
| EPS (Basic) | -0.73 | -0.74 | -0.65 | -0.52 | -0.41 | -0.39 | |
| EPS (Diluted) | -0.73 | -0.74 | -0.65 | -0.52 | -0.41 | -0.39 | |
| Free Cash Flow | -33.68 | -32.97 | -31.06 | -24.31 | -20.6 | -10.85 | |
| Free Cash Flow Per Share | -0.54 | -0.55 | -0.52 | -0.42 | -0.36 | -0.21 | |
| EBIT | -39.57 | -38.07 | -38.35 | -30.18 | -23.44 | -13.44 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.